Cyclacel Pharmaceuticals Inc.

6.39-0.1300-1.99%Vol 62.39K1Y Perf 1.12%
Apr 19th, 2021 11:38 DELAYED
BID6.33 ASK6.44
Open6.52 Previous Close6.52
Pre-Market- After-Market-
 - -%  - -
Target Price
21.33 
Analyst Rating
Strong Buy 1.00
Potential %
233.28 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     55.97
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap45.39M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
20.27 
Earnings Date
11th May 2021

Today's Price Range

6.346.70

52W Range

3.1219.25

5 Year PE Ratio Range

-0.5000-1.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-11.89%
1 Month
-21.82%
3 Months
-11.29%
6 Months
67.61%
1 Year
1.12%
3 Years
-77.82%
5 Years
-93.78%
10 Years
-99.69%

TickerPriceChg.Chg.%
CYCC6.39-0.1300-1.99
AAPL134.590.43000.32
GOOG2 298.620.86000.04
MSFT259.50-1.2400-0.48
XOM56.30-0.3600-0.64
WFC44.030.19000.43
JNJ162.510.27000.17
FB303.50-2.6800-0.88
GE13.32-0.0700-0.52
JPM153.03-0.2700-0.18
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.52-1.34-157.69
Q03 2020-0.49-0.474.08
Q02 2020-0.47-0.58-23.40
Q01 2020-2.80-1.4847.14
Q04 2019-2.40-2.80-16.67
Q03 2019-3.40-2.2035.29
Q02 2019-3.00-3.20-6.67
Q01 2019-3.80-3.0021.05
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.50-2.04Negative
6/2021 QR-0.52-1.96Negative
12/2021 FY-2.23-19.25Negative
12/2022 FY-2.4652.60Positive
Next Report Date11th May 2021
Estimated EPS Next Report-0.50
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume62.39K
Shares Outstanding7.10M
Trades Count394
Dollar Volume3.68M
Avg. Volume629.56K
Avg. Weekly Volume69.54K
Avg. Monthly Volume127.23K
Avg. Quarterly Volume679.66K

Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) stock closed at 6.52 per share at the end of the most recent trading day (a -4.4% change compared to the prior day closing price) with a volume of 99.34K shares and market capitalization of 45.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 12 people. Cyclacel Pharmaceuticals Inc. CEO is Spiro Rombotis.

The one-year performance of Cyclacel Pharmaceuticals Inc. stock is 1.12%, while year-to-date (YTD) performance is -16.52%. CYCC stock has a five-year performance of -93.78%. Its 52-week range is between 3.12 and 19.25, which gives CYCC stock a 52-week price range ratio of 20.27%

Cyclacel Pharmaceuticals Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 2.09, a price-to-sale (PS) ratio of 88.29, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -46.46%, a ROC of -40.58% and a ROE of -54.02%. The company’s profit margin is -%, its EBITDA margin is -6 220.70%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Cyclacel Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. Cyclacel Pharmaceuticals Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for Cyclacel Pharmaceuticals Inc. is Strong Buy (1), with a target price of $21.33, which is +233.28% compared to the current price. The earnings rating for Cyclacel Pharmaceuticals Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cyclacel Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cyclacel Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.27, ATR14 : 0.84, CCI20 : -141.39, Chaikin Money Flow : -0.03, MACD : -0.32, Money Flow Index : 31.49, ROC : -2.40, RSI : 41.00, STOCH (14,3) : 7.44, STOCH RSI : 0.44, UO : 39.63, Williams %R : -92.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cyclacel Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. It earns the majority of its revenue from the United Kingdom.

CEO: Spiro Rombotis

Telephone: +1 908 517-7330

Address: 200 Connell Drive, Berkeley Heights 07922, NJ, US

Number of employees: 12

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

58%42%

Bearish Bullish

52%48%

Bearish Bullish

61%39%

News

Stocktwits